{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:58:13Z","timestamp":1792123093799,"version":"4.4.0"},"reference-count":39,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute of the National Institutes of Health","doi-asserted-by":"publisher","award":["P30-CA008748"],"award-info":[{"award-number":["P30-CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Immune-related cutaneous adverse events (ircAEs) are frequent and may reduce quality of life and consistent dosing. IL12\/23 has been implicated in psoriasis, which is reminiscent of the psoriasiform\/lichenoid ircAE phenotype. We report the use of ustekinumab as a therapeutic option. Methods: Patients at Memorial Sloan Kettering Cancer Center, New York, who received immune checkpoint inhibitors and were treated with ustekinumab or had the keywords \u201custekinumab\u201d or \u201cStelara\u201d in their clinical notes between 1 March 2017 and 1 December 2022 were retrospectively identified via a database query. Documentation from initial and follow-up visits was manually reviewed, and response to ustekinumab was categorized into complete cutaneous response (CcR, decrease to CTCAE grade 0), partial cutaneous response (PcR, any decrease in CTCAE grade exclusive of decrease to grade 0), and no cutaneous response (NcR, no change in CTCAE grade or worsening). Labs including complete blood count (CBC), cytokine panels, and IgE were obtained in a subset of patients as standard of care. Skin biopsies were reviewed by a dermatopathologist. Results: Fourteen patients with psoriasiform (85.7%), maculopapular (7.1%), and pyoderma gangrenosum (7.1%) ircAEs were identified. Ten (71.4%) receiving ustekinumab had a positive response to treatment. Among these 10 responders, 4 (40%) demonstrated partial cutaneous response and 6 (60%) demonstrated complete cutaneous resolution. Six patients (42.9%) experienced interruptions to their checkpoint inhibitor treatment as a result of intolerable ircAEs, and following ircAE management with ustekinumab, two (33.3%) were successfully rechallenged with their checkpoint inhibitors. On histopathology, patients primarily had findings of interface or psoriasiform dermatitis. No patients reported an adverse event related to ustekinumab. Conclusions: Ustekinumab showed a benefit in a subset of patients with psoriasiform\/lichenoid ircAEs. No safety signals were identified. However, further prospective randomized controlled trials are needed to confirm our findings.<\/jats:p>","DOI":"10.3390\/ph16111548","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T09:16:21Z","timestamp":1698916581000},"page":"1548","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["IL12\/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events"],"prefix":"10.3390","volume":"16","author":[{"given":"Stephanie L.","family":"Gu","sequence":"first","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA"},{"name":"Department of Dermatology, Weill Cornell Medical College, New York, NY 10021, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Maier","sequence":"additional","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea P.","family":"Moy","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0747-2479","authenticated-orcid":false,"given":"Stephen","family":"Dusza","sequence":"additional","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8245-9653","authenticated-orcid":false,"given":"David M.","family":"Faleck","sequence":"additional","affiliation":[{"name":"Gastroenterology, Hepatology, and Nutrition Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY 10021, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5752-6212","authenticated-orcid":false,"given":"Neil J.","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY 10021, USA"},{"name":"Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA"},{"name":"Department of Dermatology, Weill Cornell Medical College, New York, NY 10021, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.euros.2022.12.015","article-title":"Real-world Treatment Patterns and Clinical Outcomes for Metastatic Renal Cell Carcinoma in the Current Treatment Era","volume":"49","author":"Shah","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.anai.2021.02.009","article-title":"Immune-related cutaneous adverse events due to checkpoint inhibitors","volume":"126","author":"Wang","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaci.2022.11.015","article-title":"Dermatologic immune-related adverse events to checkpoint inhibitors in cancer","volume":"151","author":"Shah","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"898790","DOI":"10.3389\/fmed.2022.898790","article-title":"High Grade Dermatologic Adverse Events Associated With Immune Checkpoint Blockade for Cancer","volume":"9","author":"Kuo","year":"2022","journal-title":"Front. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102440","DOI":"10.1016\/j.ctrv.2022.102440","article-title":"Immune checkpoint Inhibitor-Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis","volume":"109","author":"Nielsen","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S786","DOI":"10.14309\/01.ajg.0000780644.17239.03","article-title":"S1778\u2003IL12\/23 Blockade Therapy for Refractory Immune Checkpoint Inhibitor Colitis: A Case Series","volume":"116","author":"Thomas","year":"2021","journal-title":"Off. J. Am. Coll. Gastroenterol. ACG"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00004836-200110000-00006","article-title":"Side effects of corticosteroid therapy","volume":"33","author":"Buchman","year":"2001","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.4065\/81.10.1361","article-title":"Psychiatric adverse effects of corticosteroids","volume":"81","author":"Warrington","year":"2006","journal-title":"Mayo Clin. Proc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e000457","DOI":"10.1136\/esmoopen-2018-000457","article-title":"Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"4","author":"Galli","year":"2019","journal-title":"ESMO Open"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Nikita, N., Banks, J., Keith, S.W., Song, A., Johnson, J.M., Wilson, M., Sharma, S., and Lu-Yao, G. (2022). Is Timing of Steroid Exposure Prior to Immune Checkpoint Inhibitor Initiation Associated with Treatment Outcomes in Melanoma? A Population-Based Study. Cancers, 14.","DOI":"10.3390\/cancers14051296"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/1078-0432.CCR-20-2291","article-title":"Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma","volume":"27","author":"Iorgulescu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Petrelli, F., Signorelli, D., Ghidini, M., Ghidini, A., Pizzutilo, E.G., Ruggieri, L., Cabiddu, M., Borgonovo, K., Dognini, G., and Brighenti, M. (2020). Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Cancers, 12.","DOI":"10.3390\/cancers12030546"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11882-016-0620-y","article-title":"Adverse Effects of Nonsystemic Steroids (Inhaled, Intranasal, and Cutaneous): A Review of the Literature and Suggested Monitoring Tool","volume":"16","author":"Gupta","year":"2016","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40265-020-01432-7","article-title":"Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update","volume":"81","author":"Evoy","year":"2021","journal-title":"Drugs"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Yan, J., Smyth, M.J., and Teng, M.W.L. (2018). Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer. Cold Spring Harb. Perspect. Biol., 10.","DOI":"10.1101\/cshperspect.a028530"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-18-2795","article-title":"Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy","volume":"25","author":"Lim","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"13466","DOI":"10.1038\/ncomms13466","article-title":"IL-12 protects from psoriasiform skin inflammation","volume":"7","author":"Kulig","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"594735","DOI":"10.3389\/fimmu.2020.594735","article-title":"The IL-23\/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/2040622318759282","article-title":"Interleukin 23 in the skin: Role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment","volume":"9","author":"Chan","year":"2018","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","article-title":"Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn\u2019s Disease: The IM-UNITI Trial","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2021.1980536","article-title":"Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis","volume":"21","author":"Miyoshi","year":"2022","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1158\/0008-5472.CAN-12-1337","article-title":"Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state","volume":"72","author":"Teng","year":"2012","journal-title":"Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/ncb717","article-title":"Interleukin-12 suppresses ultraviolet radiation-induced apoptosis by inducing DNA repair","volume":"4","author":"Schwarz","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1046\/j.1365-2567.2000.00084.x","article-title":"Reversal of ultraviolet radiation-induced immune suppression by recombinant interleukin-12: Suppression of cytokine production","volume":"101","author":"Schmitt","year":"2000","journal-title":"Immunology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature04808","article-title":"IL-23 promotes tumour incidence and growth","volume":"442","author":"Langowski","year":"2006","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/mi.2013.101","article-title":"Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells","volume":"7","author":"Chan","year":"2014","journal-title":"Mucosal Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"8328","DOI":"10.1073\/pnas.1003251107","article-title":"IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis","volume":"107","author":"Teng","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_39","unstructured":"(2023, September 11). Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/11\/1548\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:15:57Z","timestamp":1760130957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/11\/1548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["ph16111548"],"URL":"https:\/\/doi.org\/10.3390\/ph16111548","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,2]]}}}